Biosynex (ENXTPA:ALBIO) - Share price, News & Analysis

ALBIO fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	0/6
Past Performance	5/6
Financial Health	6/6
Dividends	4/6

ALBIO Stock Overview

Biosynex SA designs, manufactures, and distributes rapid diagnostic tests in France and internationally.

Rewards

Trading at 93.4% below our estimate of its fair value

Earnings grew by 231.5% over the past year

Risk Analysis

High level of non-cash earnings

Unstable dividend track record

Biosynex Competitors

bioMérieux

ENXTPA:BIM

€10.8b

Procter & Gamble

NYSE:PG

US$340.2b

Abbott Laboratories

NYSE:ABT

US$198.3b

Church & Dwight

NYSE:CHD

US$21.5b

Price History & Performance

Summary of all time highs, changes and price drops for Biosynex
Historical stock prices
Current Share Price	€16.68
52 Week High	€28.78
52 Week Low	€13.28
Beta	-2.8
1 Month Change	-14.46%
3 Month Change	-5.71%
1 Year Change	-34.59%
3 Year Change	506.55%
5 Year Change	299.04%
Change since IPO	-7.07%

Shareholder Returns

	ALBIO	FR Medical Equipment	FR Market
7D	-9.4%	2.8%	-1.3%
1Y	-34.6%	-5.9%	-5.4%

Return vs Industry: ALBIO underperformed the French Medical Equipment industry which returned -5.9% over the past year.

Return vs Market: ALBIO underperformed the French Market which returned -5.4% over the past year.

Price Volatility

Is ALBIO's price volatile compared to industry and market?
ALBIO volatility
ALBIO Average Weekly Movement	7.5%
Medical Equipment Industry Average Movement	7.1%
Market Average Movement	6.1%
10% most volatile stocks in FR Market	10.5%
10% least volatile stocks in FR Market	3.6%

Stable Share Price: ALBIO is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: ALBIO's weekly volatility (8%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1993	260	Larry Abensur	https://www.biosynex.com

Biosynex SA designs, manufactures, and distributes rapid diagnostic tests in France and internationally. The company offers a range of rapid diagnostic tests, immunoblots, molecular biology, and point of care products for screening, diagnosis, and prevention in the areas of bacteriology, parasitology, mycology, virology, biochemistry and oncology, and women’s health, as well as COVID-19 tests and instruments. It also provides self-tests; self-measurement products, including thermometers and blood pressure monitors; and oral care and medical aid products.

Biosynex Fundamentals Summary

How do Biosynex's earnings and revenue compare to its market cap?
ALBIO fundamental statistics
Market Cap	€178.49m
Earnings (TTM)	€104.00m
Revenue (TTM)	€382.53m

1.7x

P/E Ratio

0.4x

P/S Ratio

Is ALBIO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
ALBIO income statement (TTM)
Revenue	€382.53m
Cost of Revenue	€176.12m
Gross Profit	€206.41m
Other Expenses	€102.41m
Earnings	€104.00m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	10.08
Gross Margin	53.96%
Net Profit Margin	27.19%
Debt/Equity Ratio	20.4%

How did ALBIO perform over the long term?

See historical performance and comparison

Dividends

12.0%

Current Dividend Yield

20%

Payout Ratio

Valuation

Is Biosynex undervalued compared to its fair value and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: ALBIO (€16.68) is trading below our estimate of fair value (€252.76)

Significantly Below Fair Value: ALBIO is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: ALBIO is good value based on its PE Ratio (1.7x) compared to the French Medical Equipment industry average (13.6x).

PE vs Market: ALBIO is good value based on its PE Ratio (1.7x) compared to the French market (16.3x).

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ALBIO's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: ALBIO is good value based on its PB Ratio (1x) compared to the FR Medical Equipment industry average (2.2x).

Future Growth

How is Biosynex forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

-5.1%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biosynex has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Biosynex performed over the past 5 years?

Past Performance Score

5/6

Past Performance Score 5/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

121.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ALBIO has a high level of non-cash earnings.

Growing Profit Margin: ALBIO's current net profit margins (27.2%) are higher than last year (20.4%).

Past Earnings Growth Analysis

Earnings Trend: ALBIO has become profitable over the past 5 years, growing earnings by 121.3% per year.

Accelerating Growth: ALBIO's earnings growth over the past year (231.5%) exceeds its 5-year average (121.3% per year).

Earnings vs Industry: ALBIO earnings growth over the past year (231.5%) exceeded the Medical Equipment industry 22.5%.

Return on Equity

High ROE: ALBIO's Return on Equity (62%) is considered outstanding.

Financial Health

How is Biosynex's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

Financial Position Analysis

Short Term Liabilities: ALBIO's short term assets (€198.8M) exceed its short term liabilities (€52.9M).

Long Term Liabilities: ALBIO's short term assets (€198.8M) exceed its long term liabilities (€48.2M).

Debt to Equity History and Analysis

Debt Level: ALBIO has more cash than its total debt.

Reducing Debt: ALBIO's debt to equity ratio has reduced from 34.6% to 20.4% over the past 5 years.

Debt Coverage: ALBIO's debt is well covered by operating cash flow (320.5%).

Interest Coverage: ALBIO's interest payments on its debt are well covered by EBIT (405.7x coverage).

Balance Sheet

Dividend

What is Biosynex current dividend yield, its reliability and sustainability?

Dividend Score

3/6

Dividend Score 3/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

11.99%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: ALBIO's dividend (11.99%) is higher than the bottom 25% of dividend payers in the French market (1.72%).

High Dividend: ALBIO's dividend (11.99%) is in the top 25% of dividend payers in the French market (5.01%)

Stability and Growth of Payments

Stable Dividend: Too early to tell whether ALBIO's dividend payments have been stable as they only just started paying a dividend.

Growing Dividend: Too early to tell if ALBIO's dividend payments are increasing as they only just started paying a dividend.

Earnings Payout to Shareholders

Earnings Coverage: With its low payout ratio (19.8%), ALBIO's dividend payments are well covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: With its low cash payout ratio (22.7%), ALBIO's dividend payments are well covered by cash flows.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

6.9yrs

Average board tenure

CEO

Larry Abensur

no data

Tenure

Mr. Larry Abensur has served as a Director at Biosynex S.A. since June 24, 2015 and serves as the Chief Executive Officer at Biosynex SA. He serves as the Chairman of Biosynex S.A. Mr. Abensur serves as th...

Board Members

Experienced Board: ALBIO's board of directors are considered experienced (6.9 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/23 00:00
End of Day Share Price	2022/05/23 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31